Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study | ||
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas | |
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Psicología. Instituto de Investigaciones. Psicopatología - Cátedra I | |
| dc.conicet.organizacion | Hospital Municipal General de Agudos Doctor José Penna | |
| dc.contributor.author | Sookoian, Silvia Cristina | |
| dc.contributor.author | Fernández, María Alejandra | |
| dc.contributor.author | Castaño, Gustavo Osvaldo | |
| dc.date.issued | 2005-12 | |
| dc.description.abstract | Aim: To evaluate the safety and efficacy of chronic administration of losartan on hepatic fibrosis in chronic hepatitis C patients. Methods: Fourteen patients with chronic hepatitis C non-responders (n = 10), with contraindications (n = 2) or lack of compliance (n = 2) to interferon plus ribavirin therapy and liver fibrosis were enrolled. Liver and renal function test, clinical evaluation, and liver biopsies were performed at baseline and after losartan administration at a dose of 50 mg/d during the 6 mo. The control group composed of nine patients with the same inclusion criteria and paired liver biopsies (interval 6-14 mo). Histological activity index (HAI) with fibrosis stage was assessed under blind conditions by means of Ishak's score. Subendothelial fibrosis was evaluated by digital image analyses. Results: The changes in the fibrosis stage were significantly different between losartan group (decrease of 0.5±1.3) and controls (increase of 0.89±1.27; P<0.03). In the treated patients, a decrease in fibrosis stage was observed in 7/14 patients vs 1/9 control patients (P<0.04). A decrease in sub-endothelial fibrosis was observed in the losartan group. No differences were found in HAI after losartan administration. Acute and chronic decreases in systolic arterial pressures (P<0.05) were observed after the losartan administration, without changes in mean arterial pressure or renal function. Conclusion: Chronic AT-II type 1 r eceptor (AT1R) blockade may reduce liver fibrosis in patients with chronic hepatitis C. © 2005 The WJG Press and Elsevier Inc. All rights reserved. | es |
| dc.description.fil | Fil: Sookoian, Silvia Cristina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina | |
| dc.description.fil | Fil: Fernández, María Alejandra. Universidad de Buenos Aires. Facultad de Psicología. Instituto de Investigaciones. Psicopatología - Cátedra I; Argentina | |
| dc.description.fil | Fil: Castaño, Gustavo Osvaldo. Hospital Municipal General de Agudos Doctor José Penna; Argentina | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Sookoian, Silvia Cristina; Fernández, María Alejandra; Castaño, Gustavo Osvaldo; Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study; W J G Press; World Journal of Gastroenterology; 11; 48; 12-2005; 7560-7563 | es |
| dc.identifier.eissn | 2219-2840 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 1007-9327 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/186351 | |
| dc.journal.number | 48 | es |
| dc.journal.pagination | 7560-7563 | es |
| dc.journal.pais | China | es |
| dc.journal.title | World Journal of Gastroenterology | es |
| dc.journal.volume | 11 | es |
| dc.language.iso | eng | es |
| dc.publisher | W J G Press | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3748/wjg.v11.i48.7560 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://www.wjgnet.com/1007-9327/full/v11/i48/7560.htm | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727214/ | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | ANGIOTENSIN II | es |
| dc.subject | AT1R | es |
| dc.subject | CHRONIC LIVER DISEASE | es |
| dc.subject | HEPATITIS C | es |
| dc.subject | LIVER FIBROSIS | es |
| dc.subject | LOSARTAN | es |
| dc.title | Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.b558b667-ee37-437b-981e-6aa9f015ba35_A.pdf
- Tamaño:
- 779.94 KB
- Formato:
- Adobe Portable Document Format